MX2020012418A - Adyuvante molecular. - Google Patents
Adyuvante molecular.Info
- Publication number
- MX2020012418A MX2020012418A MX2020012418A MX2020012418A MX2020012418A MX 2020012418 A MX2020012418 A MX 2020012418A MX 2020012418 A MX2020012418 A MX 2020012418A MX 2020012418 A MX2020012418 A MX 2020012418A MX 2020012418 A MX2020012418 A MX 2020012418A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- daa
- disclosed
- present disclosure
- disclosure relates
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a terapias para el tratamiento de un trastorno caracterizado por un antígeno asociado al trastorno (DAA); se describen métodos de vacunación. En particular, la divulgación describe adyuvantes moleculares de ADC anti-CD25 para su uso en la inducción o potenciación de la respuesta inmunitaria de un sujeto contra un DAA, lo que permite el tratamiento del trastorno caracterizado por el DAA. También se describen regímenes de dosificación para el tratamiento de tumores sólidos con un A. La presente divulgación se refiere al tratamiento de enfermedades patológicas, tales como cáncer, con ADC anti-CD25.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1808507.6A GB201808507D0 (en) | 2018-05-23 | 2018-05-23 | Dosage Regime |
GBGB1813067.4A GB201813067D0 (en) | 2018-08-10 | 2018-08-10 | Molecular adjuvant |
GBGB1818152.9A GB201818152D0 (en) | 2018-11-07 | 2018-11-07 | Molecular adjuvant |
PCT/EP2019/063262 WO2019224275A1 (en) | 2018-05-23 | 2019-05-22 | Molecular adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020012418A true MX2020012418A (es) | 2021-04-28 |
Family
ID=66810758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020012418A MX2020012418A (es) | 2018-05-23 | 2019-05-22 | Adyuvante molecular. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220111065A1 (es) |
EP (1) | EP3796942A1 (es) |
JP (1) | JP2021524449A (es) |
KR (1) | KR20210016562A (es) |
CN (1) | CN113286616A (es) |
AU (1) | AU2019272838A1 (es) |
BR (1) | BR112020023846A2 (es) |
CA (1) | CA3098103A1 (es) |
IL (1) | IL278819A (es) |
MX (1) | MX2020012418A (es) |
PH (1) | PH12020500670A1 (es) |
SG (1) | SG11202010469QA (es) |
WO (1) | WO2019224275A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル-マイヤーズ スクイブ カンパニー | アルファ-シヌクレインに対する抗体およびその使用 |
GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
GB201917254D0 (en) * | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
AU2022302769A1 (en) | 2021-06-29 | 2024-02-08 | Adc Therapeutics Sa | Combination therapy using antibody-drug conjugates |
CN116903713B (zh) * | 2023-07-10 | 2024-04-26 | 西南大学 | 一种微孢子虫表面抗原EcSSP1的重组蛋白、编码基因和生产方法及应用 |
CN116925198B (zh) * | 2023-08-15 | 2024-05-14 | 西南大学 | 一种微孢子虫极管蛋白EcPTP1的重组蛋白及其制备方法和应用 |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6013772A (en) | 1986-08-13 | 2000-01-11 | Bayer Corporation | Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
GB8800078D0 (en) | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel antibodies |
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5955075A (en) | 1992-03-11 | 1999-09-21 | Institute Of Virology, Slovak Academy Of Sciences | Method of inhibiting tumor growth using antibodies to MN protein |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5472693A (en) | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US6824993B2 (en) | 1995-06-06 | 2004-11-30 | Human Genome Sciences, Inc. | Antibodies that bind human prostate specific G-protein receptor HPRAJ70 |
AU2342897A (en) | 1996-03-20 | 1997-10-10 | Immunomedics Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US7011812B1 (en) | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
NZ331978A (en) | 1996-05-04 | 2000-05-26 | Zeneca Ltd | Monoclonal antibody to CEA (carcinomembryonic antigen), conjugates comprising said antibody, and their therapeutic use in an adept system |
US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US6590088B1 (en) | 1996-07-19 | 2003-07-08 | Human Genome Sciences, Inc. | CD33-like protein |
US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
US5989604A (en) | 1996-12-19 | 1999-11-23 | Adore-A-Pet, Ltd. | Xylitol-containing non-human foodstuff and method |
US5942602A (en) | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ATE473242T1 (de) | 1998-05-20 | 2010-07-15 | Immunomedics Inc | Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten |
IL147638A0 (en) | 1999-07-29 | 2002-08-14 | Medarex Inc | Human monoclonal antibodies to prostate specific membrane antigen |
US6716966B1 (en) | 1999-08-18 | 2004-04-06 | Altarex Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
US7129332B2 (en) | 2000-02-25 | 2006-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
US6759045B2 (en) | 2000-08-08 | 2004-07-06 | Immunomedics, Inc. | Immunotherapy for chronic myelocytic leukemia |
US20050019324A1 (en) | 2001-03-29 | 2005-01-27 | Wreschner Daniel H. | Peptides and antibodies to muc 1 proteins |
CA2443138A1 (en) | 2001-03-30 | 2002-10-10 | The Regents Of The University Of California | Anti-muc-1 single chain antibodies for tumor targeting |
US7183388B2 (en) | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
MXPA03010804A (es) | 2001-06-01 | 2004-11-22 | Cornell Res Foundation Inc | Anticuerpos modificados para antigeno de membrana especifico de la prostata y usos de los mismos. |
WO2003000117A2 (en) | 2001-06-21 | 2003-01-03 | Glycotech Corporation | Detection and treatment of prostate cancer |
AU2002339845B2 (en) | 2001-08-03 | 2009-03-26 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
AR036833A1 (es) | 2001-10-18 | 2004-10-06 | Bayer Corp | Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular. |
EP3184539A3 (en) | 2001-10-23 | 2017-09-13 | PSMA Development Company L.L.C. | Psma antibodies |
JP2005538682A (ja) | 2001-12-03 | 2005-12-22 | アブジェニックス・インコーポレーテッド | カルボキシックアンヒドラーゼix(caix)腫瘍抗原に対する抗体 |
BR0307216A (pt) | 2002-01-28 | 2005-12-20 | Medarex Inc | Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma) |
CA2477163C (en) | 2002-02-21 | 2010-07-27 | Institute Of Virology | Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes |
CN1649902B (zh) | 2002-03-01 | 2011-04-13 | 免疫医疗公司 | 内在化抗-cd74抗体和使用方法 |
US20090162382A1 (en) | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
ES2429112T3 (es) | 2002-04-10 | 2013-11-13 | Genentech, Inc. | Variantes de anticuerpos anti-HER2 |
US7202346B2 (en) | 2002-07-03 | 2007-04-10 | Immunogen Inc. | Antibodies to non-shed Muc1 and Muc16, and uses thereof |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
US20090252738A1 (en) | 2002-08-23 | 2009-10-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |
US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
JP4790413B2 (ja) | 2002-10-08 | 2011-10-12 | イミューノメディクス、インコーポレイテッド | 抗体療法 |
JP5354835B2 (ja) | 2002-11-07 | 2013-11-27 | イミュノジェン・インコーポレーテッド | 抗cd33抗体、及びそれを用いた急性骨髄性白血病の治療方法 |
KR20050086628A (ko) | 2002-11-15 | 2005-08-30 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
CA2514419A1 (en) | 2003-01-28 | 2004-08-12 | Proscan Rx Pharma Inc. | Prostate cancer diagnosis and treatment |
US7534431B2 (en) | 2003-01-31 | 2009-05-19 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
BRPI0407446A (pt) | 2003-02-13 | 2006-01-31 | Pharmacia Corp | Anticorpos para c-met para o tratamento de cânceres |
PL1636593T3 (pl) | 2003-06-06 | 2009-08-31 | Genentech Inc | Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met. |
CN102675462A (zh) | 2003-06-27 | 2012-09-19 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
AU2004298483A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
MXPA06009547A (es) | 2004-02-23 | 2007-01-26 | Dana Farber Cancer Inst Inc | Metodo para tratar el crecimiento celular anormal usando inhibidores de c-met y m-tor. |
EP1763367A2 (en) | 2004-07-02 | 2007-03-21 | Wilex AG | Improved adjuvant therapy of g250-expressing tumors |
KR20150140417A (ko) | 2004-07-22 | 2015-12-15 | 제넨테크, 인크. | Her2 항체 조성물 |
NZ552485A (en) | 2004-08-05 | 2009-11-27 | Genentech Inc | Humanized anti-cmet antagonists |
CA2583208C (en) | 2004-10-15 | 2015-08-25 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006050834A2 (en) | 2004-11-09 | 2006-05-18 | Philogen Spa | Antibodies against tenascin-c |
CA2589374C (en) | 2004-11-30 | 2016-05-03 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
JP5249587B2 (ja) | 2005-02-18 | 2013-07-31 | メダレックス, インク. | フコシル残基を欠く前立腺特異的膜抗原(psma)に対するモノクローナル抗体 |
US7615529B2 (en) | 2005-03-25 | 2009-11-10 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
JP2009506790A (ja) | 2005-09-07 | 2009-02-19 | メディミューン,エルエルシー | 毒素とコンジュゲートしたeph受容体抗体 |
ATE504565T1 (de) | 2005-10-07 | 2011-04-15 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
WO2007126799A2 (en) | 2006-03-30 | 2007-11-08 | Novartis Ag | Compositions and methods of use for antibodies of c-met |
EP2163563A1 (en) | 2006-03-31 | 2010-03-17 | Massachusetts Institute of Technology | Treatment of tumors expressing mutant EGF receptors |
TWI429658B (zh) | 2006-06-07 | 2014-03-11 | Bioalliance Cv | 辨認癌症細胞上表現的cd43與cea之含碳水化合物抗原決定區的抗體及其使用方法 |
RU2009107277A (ru) | 2006-08-03 | 2010-09-10 | Астразенека Аб (Se) | АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ |
ES2457072T3 (es) | 2006-08-14 | 2014-04-24 | Xencor, Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
CN101535332A (zh) | 2006-10-31 | 2009-09-16 | 免疫基因公司 | 用于提高抗体产量的方法 |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
PT2211904T (pt) | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Agentes de ligação a cd19 e seus usos |
WO2009056342A1 (en) | 2007-11-02 | 2009-05-07 | Wilex Ag | Binding epitopes for g250 antibody |
AU2008338313B2 (en) | 2007-12-18 | 2014-01-16 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
US20090169550A1 (en) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Therapy of rituximab-refractory rheumatoid arthritis patients |
PT2242772E (pt) | 2007-12-26 | 2015-02-09 | Biotest Ag | Imunoconjugados dirigidos contra cd138 e as suas utilizações |
EP2238168B8 (en) | 2007-12-26 | 2014-07-23 | Biotest AG | Agents targeting cd138 and uses thereof |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
NZ590330A (en) | 2008-07-21 | 2012-08-31 | Immunomedics Inc | Structural variants of anti-cd20 antibodies for improved therapeutic characteristics |
ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
US8734795B2 (en) | 2008-10-31 | 2014-05-27 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
WO2010051391A1 (en) | 2008-10-31 | 2010-05-06 | Facet Biotech Corporation | Use of anti-cs1 antibodies for treatment of rare lymphomas |
PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
NZ596807A (en) | 2009-05-06 | 2013-09-27 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
EP2427490A1 (en) | 2009-05-07 | 2012-03-14 | Novartis AG | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
PL3023438T3 (pl) | 2009-09-03 | 2020-07-27 | Merck Sharp & Dohme Corp. | Przeciwciała anty-gitr |
CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
US20110028129A1 (en) | 2009-10-13 | 2011-02-03 | Hutchison James W | Proximity Triggered Profile-Based Wireless Matching |
KR101671378B1 (ko) | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
KR101748707B1 (ko) | 2009-11-27 | 2017-06-20 | 삼성전자주식회사 | c-Met에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트 |
ES2594893T3 (es) | 2009-12-16 | 2016-12-23 | Abbvie Biotherapeutics Inc. | Anticuerpos anti HER2 y sus usos |
US8609095B2 (en) | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들 |
HUE035503T2 (en) | 2012-10-02 | 2018-05-02 | Bristol Myers Squibb Co | Combination of anti-anti-antibodies and anti-PD-1 antibodies to treat cancer |
PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
CN107011441B (zh) | 2013-09-13 | 2020-12-01 | 百济神州(广州)生物科技有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
BR112016013963A2 (pt) | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
SG11201608106PA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
DK3309174T3 (da) | 2014-07-11 | 2022-06-07 | Ventana Med Syst Inc | ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf |
EP3169361B1 (en) | 2014-07-15 | 2019-06-19 | F.Hoffmann-La Roche Ag | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
RU2017119231A (ru) | 2014-11-03 | 2018-12-06 | Дженентек, Инк. | Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40 |
WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
CA2968447A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates and their use to treat neoplasms |
US10983128B2 (en) | 2015-02-05 | 2021-04-20 | Bristol-Myers Squibb Company | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy |
GB201506405D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
MY189692A (en) | 2015-05-07 | 2022-02-26 | Memorial Sloan Kettering Cancer Center | Anti-ox40 antibodies and methods of use thereof |
GB201507827D0 (en) * | 2015-05-07 | 2015-06-17 | Adc Therapeutics Sarl | Diagnostic test |
US20160347848A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
WO2016196792A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
WO2017004016A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
GB201513607D0 (en) * | 2015-07-31 | 2015-09-16 | Feingold Jay M | Pyrrolobenzodiazepine-antibody conjugates |
EP3408294A1 (en) | 2016-01-25 | 2018-12-05 | Pfizer Inc. | Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer |
KR20230082055A (ko) * | 2016-06-17 | 2023-06-08 | 마젠타 테라퓨틱스 인코포레이티드 | 세포의 고갈을 위한 조성물 및 방법 |
JP2019534882A (ja) * | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドMedImmune Limited | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
BR112019021680A2 (pt) * | 2017-04-20 | 2020-05-12 | Adc Therapeutics Sa | Terapia de combinação com conjugado anticorpo-fármaco anti-cd25?? |
CA3064681A1 (en) * | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd25 adc |
-
2019
- 2019-05-22 MX MX2020012418A patent/MX2020012418A/es unknown
- 2019-05-22 CA CA3098103A patent/CA3098103A1/en active Pending
- 2019-05-22 KR KR1020207037115A patent/KR20210016562A/ko unknown
- 2019-05-22 EP EP19729452.3A patent/EP3796942A1/en not_active Withdrawn
- 2019-05-22 BR BR112020023846-5A patent/BR112020023846A2/pt not_active Application Discontinuation
- 2019-05-22 AU AU2019272838A patent/AU2019272838A1/en active Pending
- 2019-05-22 JP JP2020564541A patent/JP2021524449A/ja active Pending
- 2019-05-22 SG SG11202010469QA patent/SG11202010469QA/en unknown
- 2019-05-22 US US17/057,486 patent/US20220111065A1/en active Pending
- 2019-05-22 CN CN201980034789.3A patent/CN113286616A/zh active Pending
- 2019-05-22 WO PCT/EP2019/063262 patent/WO2019224275A1/en unknown
-
2020
- 2020-11-18 IL IL278819A patent/IL278819A/en unknown
- 2020-11-19 PH PH12020500670A patent/PH12020500670A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3098103A1 (en) | 2019-11-28 |
IL278819A (en) | 2021-01-31 |
AU2019272838A1 (en) | 2020-11-26 |
WO2019224275A1 (en) | 2019-11-28 |
KR20210016562A (ko) | 2021-02-16 |
SG11202010469QA (en) | 2020-11-27 |
BR112020023846A2 (pt) | 2021-04-13 |
PH12020500670A1 (en) | 2021-06-28 |
US20220111065A1 (en) | 2022-04-14 |
EP3796942A1 (en) | 2021-03-31 |
CN113286616A (zh) | 2021-08-20 |
JP2021524449A (ja) | 2021-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500670A1 (en) | Molecular adjuvant | |
MX2019010972A (es) | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. | |
MX2020001996A (es) | Moleculas anti-cd137 y uso de estas. | |
EA201890355A1 (ru) | Новые способы индукции иммунного ответа | |
BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
EA201790799A1 (ru) | Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей | |
EA201491171A1 (ru) | Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения | |
EA201800148A1 (ru) | Оспенная вакцина для лечения рака | |
CA2759013C (en) | Combination immunotherapy compositions against cancer and methods | |
EA201590822A1 (ru) | Адъювантная терапия ингибитором киназы семейства tec | |
UA109108C2 (uk) | Антитіло до pd-l1 та його застосування для посилення функції t-клітин | |
WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
MX2017000630A (es) | Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral. | |
BR112018071683A2 (pt) | método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente | |
NZ729519A (en) | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin | |
PH12016502445A1 (en) | Antibodies directed against cd127 | |
EA201391183A1 (ru) | Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин | |
EA201891124A3 (ru) | Новые мукозные адъюванты и системы доставки | |
WO2018083220A3 (en) | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines | |
WO2015153857A8 (en) | Methods for enhancing the efficacy of a tumor-directed immune response | |
MX2018009506A (es) | Vacunas contra el cáncer y métodos de tratamiento que las utilizan. | |
JP2018522880A5 (es) | ||
PH12019500851A1 (en) | Tolerogenic dna vaccine | |
MX2022004086A (es) | Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos. |